BETA DRUGS Latest Share Price (BETA)
TODAY IN ONE LINE
BETA is little changed at ₹2068.00 — a quiet consolidation day.
With a market cap of ₹2,301.65 Cr., it trades at a P/E of 50.32. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BETA DRUGS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 55.5% YoY
- ●Poor Capital ReturnsLow ROE of 9.6%
- ●Expensive ValuationTrading at a high P/E ratio of 53.6x
Latest BETA DRUGS News
What changed recently?
Recent events, corporate actions, and announcements.
BETA DRUGS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BETA DRUGS, framed against the sector median so the premium or discount is obvious at a glance.
BETA DRUGS trades at a P/E of 50.32× and P/B of 8.53×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BETA DRUGS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BETA DRUGS — derived from the latest tape, not yesterday's close.
BETA DRUGS last traded at ₹2,068 with an intraday range of ₹2,054.6–₹2,100 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2068.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2184.60 | +116.60 | +5.64% |
| R3 | 2139.20 | +71.20 | +3.44% |
| R2 | 2119.60 | +51.60 | +2.50% |
| R1 | 2093.80 | +25.80 | +1.25% |
| PIVOT | 2074.20 | 6.20 | 0.30% |
| CURRENT | 2068.00 | — | — |
| S1 | 2048.40 | -19.60 | -0.95% |
| S2 | 2028.80 | -39.20 | -1.90% |
| S3 | 2003.00 | -65.00 | -3.14% |
| S4 | 1957.60 | -110.40 | -5.34% |
BETA is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹2054.6–₹2100
Trading Inside opening range
BETA DRUGS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BETA DRUGS — consolidated or standalone — with margins, YoY growth and key ratios inline.
BETA DRUGS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,301.65 Cr. and reported EPS of ₹5.35.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 362 | 385 ▲ 6.2% |
| Sales Growth YoY %Derived | — | 6.20% |
| Other Income | 6 | 11 ▲ 73.7% |
| Total Income | 369 | 396 ▲ 7.4% |
| 171 | 171 ▼ 0.1% | |
| Gross ProfitDerived | 191 | 214 ▲ 11.9% |
| Gross Margin %Derived | 52.71% | 55.52% |
| 116 | 138 ▲ 18.5% | |
| EBITDA (Operating Profit)Derived | 75 | 76 ▲ 1.4% |
| OPM %Derived | 20.59% | 19.67% |
| 15 | 32 ▲ 117.4% | |
| Profit Before Tax (PBT) | 57 | 54 ▼ 4.5% |
| 15 | 13 ▼ 11.3% | |
| Effective Tax %Derived | 25.54% | 23.74% |
| Total Profit for Period | 42 | 41 ▼ 2.2% |
| Net Profit (Owner's PAT)Derived | 42 | 41 ▼ 2.2% |
| Net Profit Margin %Derived | 11.71% | 10.78% |
| PAT Growth YoY %Derived | — | -2.21% |
| Earnings Per Share (EPS ₹) | 42.02 | 40.92 ▼ 2.6% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.4% |
| Other Comprehensive Income (Net of Tax) | — | 0 |
| Total Expenses (incl. D&A & Interest) | 312 | 342 ▲ 9.6% |
| Material Cost % of RevenueDerived | 48.51% | 45.17% |
| Employee Cost % of RevenueDerived | 9.38% | 17.67% |
| Other Cost % of RevenueDerived | 22.75% | 18.18% |
| Interest Coverage (x)Derived | 8.88x | 3.82x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 362 | 385 ▲ 6.2% | |
| Sales Growth YoY %Derived | — | 6.20% | |
| Other Income | 6 | 11 ▲ 73.7% | |
| Total Income | 369 | 396 ▲ 7.4% | |
171 | 171 ▼ 0.1% | ||
| Gross ProfitDerived | 191 | 214 ▲ 11.9% | |
| Gross Margin %Derived | 52.71% | 55.52% | |
116 | 138 ▲ 18.5% | ||
| EBITDA (Operating Profit)Derived | 75 | 76 ▲ 1.4% | |
| OPM %Derived | 20.59% | 19.67% | |
15 | 32 ▲ 117.4% | ||
| Profit Before Tax (PBT) | 57 | 54 ▼ 4.5% | |
15 | 13 ▼ 11.3% | ||
| Effective Tax %Derived | 25.54% | 23.74% | |
| Total Profit for Period | 42 | 41 ▼ 2.2% | |
| Net Profit (Owner's PAT)Derived | 42 | 41 ▼ 2.2% | |
| Net Profit Margin %Derived | 11.71% | 10.78% | |
| PAT Growth YoY %Derived | — | -2.21% | |
| Earnings Per Share (EPS ₹) | 42.02 | 40.92 ▼ 2.6% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.4% | |
| Other Comprehensive Income (Net of Tax) | — | 0 | |
| Total Expenses (incl. D&A & Interest) | 312 | 342 ▲ 9.6% | |
| Material Cost % of RevenueDerived | 48.51% | 45.17% | |
| Employee Cost % of RevenueDerived | 9.38% | 17.67% | |
| Other Cost % of RevenueDerived | 22.75% | 18.18% | |
| Interest Coverage (x)Derived | 8.88x | 3.82x |
BETA DRUGS segment analysis : revenue and profit mix.
Disclosed business segments at BETA DRUGS with their share of revenue and profit, switchable between consolidated and standalone reporting.
BETA DRUGS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BETA DRUGS.
Our AI distills the core fundamental drivers supporting BETA DRUGS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 65 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.37. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
BETA DRUGS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BETA DRUGS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BETA DRUGS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BETA DRUGS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BETA DRUGS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BETA DRUGS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BETA DRUGS stood at 52.2% of traded volume, against a 20-day average of 52.7%.
BETA DRUGS announcements: results, concalls, ratings, M&A.
Filings BETA DRUGS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BETA DRUGS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 84 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Beta Drugs Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Beta Drugs Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Beta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
General Updates
Beta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of…
Shareholders meeting
Beta Drugs Limited has informed the Exchange regarding Notice of undefined to be held on September 30, 2026
Investor decks & rating reports.
BETA DRUGS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BETA DRUGS has declared, sequenced by announce and record date.
BETA DRUGS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BETA DRUGS: business, sector, key facts.
What BETA DRUGS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BETA DRUGS is a listed Indian equity, listed as NSE: BETA.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BETA DRUGS (BETA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BETA DRUGS (BETA)?
The current share price of BETA DRUGS (BETA) is ₹2,068.00. Today, the stock has gained by ₹3.10 (0.15%), trading in a range of ₹2,054.60 to ₹2,100.00. The stock opened at ₹2,054.60 with a trading volume of 2,810 shares.
02Is BETA DRUGS stock a good investment for long-term?
BETA DRUGS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,301.65 Cr., P/E ratio of 50.32, ROE of 9.58%, and ROCE of 14.63%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BETA DRUGS stock?
The 52-week high price of BETA DRUGS (BETA) is ₹2,807.90, while the 52-week low is ₹990.10. Currently trading at ₹2,068.00, the stock is 108.87% above its 52-week low and 26.35% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BETA DRUGS stock at the current price?
Whether to buy BETA DRUGS stock at ₹2,068.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.32 and P/B ratio of 8.53. Today's performance shows a gain of 0.15%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BETA DRUGS and when is the next dividend?
BETA DRUGS offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹2,068.00, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹9.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of BETA DRUGS?
BETA DRUGS's key financial metrics include: P/E Ratio: 50.32, P/B Ratio: 8.53, ROE: 9.58%, ROCE: 14.63%, Dividend Yield: 0%, EPS: ₹5.35, Book Value: ₹220.79, and Debt-to-Equity: 0.87. The company's market cap stands at ₹2,301.65 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is BETA DRUGS stock performing today in the market?
BETA DRUGS stock opened at ₹2,054.60 and is currently trading at ₹2,068.00, showing a gain of ₹3.10 (0.15%). The intraday high is ₹2,100.00 and low is ₹2,054.60. The trading volume stands at 2,810 shares, indicating moderate market participation today.
08What is the P/E ratio of BETA DRUGS and what does it indicate?
BETA DRUGS has a Price-to-Earnings (P/E) ratio of 50.32, which means investors are willing to pay 50.32 for every ₹1 of earnings. With an EPS of ₹5.35, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about BETA DRUGS (BETA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.